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ABSTRACT 
Selective IgA deficiency (IgAD) is the most common primary immunodeficiency disorder in 
Caucasians and is defined as serum IgA concentrations below or equal to 0.07 g/l, with normal serum 
concentrations of IgM and IgG, in individuals 4 years of age or older. The prevalence of IgAD is 
approximately 1:600 in the general population and recent results have shown that patients with IgAD 
have significantly poorer physical health and an increased risk of early death.  
The domestic dog is more than just a companion and working animal. The almost 400 distinct modern 
dog breeds represent great phenotypical diversity and there are more than 350 naturally occurring 
genetic diseases in dogs which clinically resemble the corresponding human diseases. As a result of 
domestication, the dog’s genome is characterised by long haplotype blocks and linkage 
disequilibrium (LD) making the dog an appealing model for genetic studies of human diseases.  
Low serum IgA concentrations in dogs have been reported to clinically resemble human IgAD. 
However, even though the literature on IgA concentrations in dogs is extensive, the normal range of 
serum IgA as well as a generally accepted cut-off value for IgAD deficiency has not yet been 
established. 
We performed an extensive screen of serum IgA concentrations in more than 1,500 dogs from 
22 breeds. Dog breed-specific differences in the prevalence of IgAD indicate the involvement of 
genetic factors in the development of the disease. Furthermore, certain dog breeds were found to stand 
out as high-risk breeds. 
Genome-wide association studies (GWAS) in selected high-risk breeds show that IgAD is associated 
with genes involved in B cell development and haematopoiesis. Additionally, serum IgA 
concentrations were found to play an important role in the aetiology of canine atopic 
dermatitis (CAD), an autoimmune disease in dogs.  
Molecular identity allowed the quantification of IgA in serum samples from Canadian and 
Scandinavian wolves with the same antibodies as those used in dogs. Interestingly, wolves from 
Scandinavia show significantly lower IgA concentrations as compared to Canadian wolves. Due to its 
size, the Scandinavian wolf population is prone to inbreeding and therefore, it is known to suffer from 
a decrease in genetic variation. Further analyses are needed to investigate whether Scandinavian 
wolves and dogs with a high-risk profile for IgAD share certain genetic factors.  
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1 INTRODUCTION 
1.1 HUMAN IGA 
Immunoglobulin (Ig) A accounts for at least 70 % of all Igs produced in the human body. It is the 
predominant Ig class at the mucosal sites (secretory IgA) and the second most prevalent antibody 
class, after IgG, in serum [1].  
Humans have two functional gene loci encoding the α-heavy chain (CHα) domain of the antibody 
molecule, resulting in two IgA subclasses (IgA1 and IgA2). The predominant difference between 
IgA1 and IgA2 is the length of the hinge region [1, 2].  
Whilst serum IgA is predominantly monomeric IgA1, the secretory IgA is polymeric, mainly dimeric, 
with an increased proportion of IgA2 [2]. Serum IgA is produced in the bone marrow while secretory 
IgA is produced locally at the mucosal surfaces, in direct contact with the environment [2]. In the vast 
majority of individuals, there is a high correlation between serum IgA concentrations and mucosal 
IgA concentrations [3]. 
As the basis of the secretory immune system, IgA protects the lining of the gastrointestinal, respiratory 
and genitourinary tracts from invading pathogens by neutralising antigens and preventing the 
adherence of bacteria [2, 4, 5]. The function of serum IgA is less clear, however, there is evidence that 
serum IgA triggers effector functions [2, 6].  
Genome-wide association studies (GWAS) found the regulation of normal serum IgA concentrations 
in humans to be associated with members of the tumour necrosis factor (TNF) ligand superfamily. 
Interestingly, both candidate loci are involved in the regulation of B cell proliferation [7, 8]. 
 
1.2 SELECTIVE IGA DEFICIENCY IN HUMANS 
Selective IgA deficiency (IgAD) is defined as serum IgA concentrations equal to or less than 0.07 g/l, 
with normal concentrations of IgG and IgM, in individuals four years of age or older [9]. IgAD is the 
most common primary immunodeficiency in humans and its frequency ranges from 1:143 in Saudi 
Arabia [10] to 1:18,500 in Japan [11]. In Sweden, the frequency is around 1:600 [12]. 
IgAD can appear or disappear spontaneously [2]. Furthermore, a transient form of the deficiency can 
be induced by captopril, penicillamine and other drugs [13]. Until recently, it was believed that only 
one third of the patients with IgAD have an increased risk of recurrent infections at mucosal sites and 
an increased predisposition for autoimmune diseases, such as rheumatoid arthritis and systemic lupus 
erythematosus (SLE), allergy and gastrointestinal infections [14–16]. Recent studies, however, show 
that IgA-deficient individuals have significantly poorer physical health [17] and an increased risk of 
early death [18]. 
The genetic background of IgAD is complex. It is assumed that regulatory mechanisms in the 
production or secretion of IgA are the cause of the deficiency, since both CHα genes are expressed and 
functional in individuals with IgAD and no mutations have been identified within the coding regions 
of these genes [19]. 
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There is a strong association of IgAD with the major histocompatibility complex (MHC) region, in 
particular the human leucocyte antigen (HLA) [20]. Up to 45 % of IgAD patients harbour at least one 
copy of the risk-conveying HLA-B*08, DRB1*03, DQB1*02 haplotype [21, 22] in comparison to 
16 % in the general population [23]. Other haplotypes, like the HLA-DRB1*07, DQB1*02 and 
DRB1*01, DQB1*05 are also associated with IgAD [24]. The HLA-DRB1*15, DQB1*06 haplotype 
has been shown to confer almost complete protection against the disorder [24–26]. 
Furthermore, non-MHC genes (interferon induced with helicase C domain 1 [IFIH1] and C-type lectin 
domain family 16 [CLEC16A]) and to a lesser extent, several autoimmunity risk alleles have been 
found to be associated with IgAD [27]. Lastly, missense mutations in the TNF receptor family 
member TACI, mediating isotype switching in B cells, were reported in 1:16 individuals with 
IgAD [28]. 
 
1.3 MURINE DISEASE MODELS FOR IGAD 
The foremost model for genetic studies in mammals has been the mouse, but with significant 
limitations. Spontaneously occurring diseases in humans must be induced in mice, thus limiting the 
possibility to study complex, polygenic human diseases. 
Until today, there is no animal model that fully resembles the manifestation of IgAD in humans. In 
mice, the phenotype is usually genetically or experimentally induced and therefore, resembles the 
human disease only to a limited extent [13].  
Several knockout mice have been generated by targeted deletion of either the joining chain [29], 
which links two monomeric IgA molecules, or the IgA switch region and/or parts of the antibody’s 
constant region. Although the secretion of IgA was successfully impaired, the concentrations of IgM 
and (subclasses of) IgG in serum and/or secretion increased significantly [30–34].  
Another strategy to artificially create IgA-deficient mouse models is the disruption or deletion of 
cytokine or cytokine receptor genes crucial for B cell development, such as lymphotoxin α [35, 36], 
tumour necrosis factor superfamily (APRIL) [37] and the interleukin (IL)-5 receptor [38]. With the 
exception of IL-5 receptor, a significant decrease in serum IgA concentration has been observed in 
these models. However, the observed side effects have been substantial. They range from disrupted 
development of secondary lymphoid organs [35] to an increased number of effector and memory 
B and T cells [37].   
More or less successful, the murine disease models are used to investigate the protection from 
infection, such as influenza [32] and rotavirus [31, 39], through secretory IgA.  
 
1.4 DOMESTICATION OF THE DOG 
The domestic dog (Canis lupus familiaris) emerged from its wild ancestor, the gray wolf 
(Canis lupus), through domestication; a process that started around 15,000 years ago [40]. The 
domestication is characterised by two narrow genetic bottlenecks where only a limited number of wild 
ancestors contributed to the generation of a very restricted gene pool (Figure 1) [40, 41]. These genetic 
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restrictions are the reason for considerably short haplotype blocks on a species level and long 
breed-specific haplotypes [40].  
The haplotype blocks and the linkage disequilibrium (LD) in the whole domesticated dog population 
are about 10 kilo base pairs (kb) and thus, shorter than in humans [40, 41]. LD breaks down over 
time [42]; as the first genetic bottleneck occurred around 15,000 years ago, there was enough time for 
breakdown of the haplotype blocks in the whole dog population [41]. 
There are nearly 400 distinct dog breeds showing great phenotypic diversity for morphology, 
physiology and behaviour. The phenotypic variety was generated based on few founder animals and 
stringent breeding strategies. The overall genetic drift led to a loss of genetic diversity within breeds 
and a greater divergence among them [43]. Long breed-specific haplotype blocks of 0.1 to 1 mega 
base pairs (Mb) and a LD that is 40 to 100𝑥 more extensive than in humans are the result [41 ,44, 45]. 
The generation of modern dog breeds started around 200 years ago [41], not leaving enough time for 
the haplotypes and the LD to break down. As a consequence, the dog genome displays unique features 
making it an excellent model for genetic studies. 
 
 
Figure 1. The domestication of modern dog breeds is characterised 
by two genetic bottlenecks. The first one occurred around 15,000 
years ago when the domestic dog diverged from the gray wolves. 
At the time of the creation of modern dog breeds, around 200 years 
ago, a very restricted number of founder animals contributed to the 
genetic pool. As a consequence, our modern dog breeds display 
long haplotypes and long LD in a dog breed-specific manner. This 
figure was adapted from Karlsson and Lindblad-Toh, Nature 
Reviews. Genetics. 2008 Sep; 9(9): 713-725, with permission from 
Nature Publishing Group. 
 
1.5 THE CANINE LEUCOCYTE ANTIGEN  
The dog leucocyte antigen (DLA) is the canine counterpart of the HLA. Like in all vertebrates, the 
genes inside the DLA are essential for the presentation of foreign and self-peptides to the immune 
system [46, 47]. The DLA is thought to be under balancing selection to maintain the required 
diversity. The proposed selection mechanisms are based on providing resistance for diseases and 
parasites, maternal-foetal interactions and mate choice to avoid inbreeding [48–50].  
Low levels of genetic diversity have been suggested to increase vulnerability to infectious 
diseases [51–53]. Furthermore, a higher level of heterozygosity in the HLA region in humans is 
thought to provide an advantage in fighting viral diseases [54–57]. Similar results were found for 
some wildlife species [58], but not all [49, 59–61]. 
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The structure of the DLA was identified through large-scale mapping studies [62]. In general, it is 
divided into class I, II and III regions [63, 64]. DLA class I and II genes, involved in the processing 
and presenting of antigens [65], are characterised by low mutation rates and high levels of 
polymorphism [66–68]. In addition, these genes display a significant sequence homology with the 
corresponding HLA regions in humans [69–71]. 
The DLA class II complex is composed of a tightly linked cluster of three functional genes (DRB1, 
DQA1 and DQB1) and one pseudogene (DRB2) on canine chromosome (CFA) 12. The complex 
shows high inter-breed and low intra-breed variation of alleles and haplotypes resulting in a 
characteristic distribution of DLA alleles for individual breeds (Table 1) [67, 72, 73]. Theoretically, 
there is a great capacity for allelic variation within the DLA class II region. However, this potential is 
limited, due to the natural LD and the breeding restrictions [74].  
 
Table 1. Distribution of selected DLA alleles in dogs. This table was adapted from Kennedy et al., 
Tissue Antigens. 2002 Mar; 59(3): 194-204, with permission from John Wiley and Sons. 
DLA allele Beagle  German shepherd Labrador retriever  Golden retriever 
DRB1*n 
    
001 40 16 23 6 
002 13 7 - - 
008 13 - 3 - 
011 2 32 1 - 
012 1 2 31 54 
015 17 38 22 14 
DQA*n 
    
00101 44 13 25 13 
00201 2 15 2 1 
00301 15 - 6 4 
00401 1 10 32 64 
00601 1 37 20 1 
00701 1 16 2 1 
00901 31 - - - 
DQB1*n 
    
101 13 - - - 
201 50 - 10 - 
401 3 - 10 - 
701 13 - 15 - 
1303 3 - 10 - 
1701 - - 35 - 
2301 - - 15 - 
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1.6 CANINE DISEASE MODEL 
After humans, the dog is the most intensively studied animal in medical practice with detailed records 
of its family history [41, 75]. There are more than 350 naturally occurring genetic diseases described 
in dogs that clinically resemble the corresponding human disease [75, 76]. The strong selection of 
certain traits, popular sires and inbreeding during the domestication of the dog led to an enrichment of 
disease mutations in different breeds. Often these diseases occur exclusively in a limited number of 
breeds, due to the enrichment of risk alleles suggesting a heritable component [77].  
Due to the similar genomic content and genetic predisposition, the dog is an excellent model for 
mapping disease-causing genes of common and even complex diseases [41, 78]. Gene mapping was 
successfully performed for narcolepsy [79], copper toxicosis [80, 81], ichthyosis [82], haemophilia, 
retinal degeneration, and muscular dystrophy [83] amongst others. 
The dog’s many advantages, beside its particular genetics, make it a superior model system for 
translational medicine. In 2005, the first high-quality draft sequence of the euchromatic genome of a 
dog, a female boxer named Tasha, was published [41]. Additional analysis of the canine haplotype 
structure and a dense single nucleotide polymorphism (SNP) map enabled the study of even more 
complex disease backgrounds, including human aging and Alzheimer’s disease [84], cancer [85], 
SLE [86], as well as the environmental contributions to diseases, aging, and disease heredity [83]. 
There are further advantages the canine disease models have to offer. The dog is a companion animal 
with which we share our environment and it receives good care, including medical care. The lifespan 
of a dog is approximately seven times shorter than that of humans, making disease development and 
progression shorter. Reduced regulatory guidelines and increasing acceptance by regulatory bodies 
make clinical trials in dogs even more attractive [83, 85]. 
The enormous genetic diversity between different dog breeds is the cause for some limitations of 
canine disease models. Breed-specific differences in physiology and metabolism make a 
generalisation of results difficult. This is particularly the case in pharmacodynamics and 
pharmacokinetics [87]. Compared to rodent models, their generation time is longer, they are more 
expensive to house, due to their size, and use for research purposes is more strictly regulated [83, 84].  
 
1.7 IGA AND IGAD IN DOGS 
In contrast to humans, only a single CHα gene has been described in dogs [88]. It occurs in four 
different allelic variants which differ mainly in the length of the hinge region [89]. The polymeric, 
predominantly dimeric, mucosal IgA is produced by plasma cells at the mucosal sites of the 
intestine [90, 91]. Interestingly, mucosal IgA represents the main source of serum IgA in dogs [92]. 
Also, in dogs there is a correlation between IgA concentration and age. While the concentrations are 
low [93] or even undetectable [94] in young animals, they later increase with ageing [95, 96].  
The quantification of immunoglobulins is commonly used in dogs to assess immune function. Still, 
the normal range of serum IgA and a generally accepted, physiologically proven cut-off value for 
IgAD have not been established yet. This is partially due to the strong variation of IgA concentrations 
among different dog breeds [97]. 
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Previously suggested cut-offs in different dog breeds range from 0.15 g/l [98, 99] to 0.3 g/l [100]. 
Selected dog breeds, including the Chinese Shar Pei (SP) [98, 100] and selected Beagle 
dogs [95, 101], show innately low IgA concentrations or even overt deficiency. For German shepherd 
dogs (GSD), conflicting results have been published. Some studies report no difference in serum IgA 
concentrations [102] and faecal samples [103] as compared to other breeds. Other studies find lower 
IgA concentrations in serum [104–107], tears [108], faeces [109] and secretions of duodenal 
explants [110].  
The majority of animals displays no clinical symptoms [107]. In terms of recurrent infection, 
especially of the skin and the upper respiratory tract [95, 100, 105] and the increased susceptibility to 
immune-mediated diseases [95], low IgA concentrations in dogs clinically resemble human IgAD. 
Furthermore, intestinal bacterial overgrowth has been found in dogs with IgAD [105, 106].  
 
1.8 IGA CONCENTRATIONS IN WOLVES 
Despite all the work on IgA concentrations in dogs, very little is known on Ig concentrations in 
wolves. This is remarkable, especially since the grey wolf is considered to be the ancestor of the 
dog [111].  
One study on serum IgE in wolves found concentrations approximately twice as high as the ones in 
dogs [112]. 
 
1.9 CANINE ATOPIC DERMATITIS 
Canine atopic dermatitis (CAD) is a complex disease involving immune dysregulation, allergic 
sensitisation, skin barrier defects, microbial colonisation and environmental factors [113]. It is an 
inflammatory and pruritic allergic skin disease with clinical manifestations similar to human atopic 
dermatitis. CAD develops in young dogs between six months and three years of age [114]. It affects 
10-15 % of all dogs [113–116]. 
There is a genetic component with a strong breed predisposition (e.g. for Labrador retriever [LR]) 
involved in CAD [117, 115]. Environmental factors have been found to be crucial for the development 
of CAD and this might explain its seasonal manifestations [118]. 
Most dogs with CAD produce IgE antibodies directed towards environmental allergens [119, 120].  
However, IgE concentrations are not correlated to the disease course [121]. Moreover, total IgE 
concentrations in normal and atopic dogs have not been found to differ significantly [122].  
Allergic symptoms manifest in the muzzle, on the ears, the paws, the extremities, the ventrum and flex 
zones in the form of pruritus and erythema [123].  
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2 AIMS 
 
2.1 GENERAL AIM 
 
The aim of this thesis is to evaluate the potential of a canine disease model for the study of genetic risk 
factors associated with IgAD in humans.  
 
 
2.2 SPECIFIC AIMS 
 
The specific aims of this thesis are to investigate the prevalence of IgAD in different dog breeds, 
identify dog breeds with a high-risk profile for IgAD and to analyse genomic loci associated with 
IgAD in selected high-risk breeds using GWAS.  
Furthermore, the breed-specific differences in the prevalence of IgAD raised the question as to 
whether canine IgAD is a breeding-enriched phenomenon. To address this question, serum IgA 
concentrations in wolves from North America and Scandinavia have been analysed. 
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3 MATERIALS AND METHODS 
3.1 SAMPLE COHORTS 
3.1.1 Dog samples 
Blood samples (ethylenediaminetetraacetic acid [EDTA] blood for the extraction of deoxyribonucleic 
acid [DNA] and serum for IgA quantification) were collected from 1,623 privately owned, purebred 
dogs aged between 0.5 and 17 years in collaboration with veterinaries in the United States, Sweden 
and Switzerland (Table 2). The samples were obtained all year round between 2007 and 2013. Owner 
consent was collected for each dog.  
Serum was isolated from blood samples after centrifugation and stored at -20 °C/ -80 °C until use. The 
sampling was conformed to the approval of the Swedish Animal Ethical Committee, the Swedish 
Animal Welfare Agency, the Broad Institute (Cambridge, MA, USA) and the canton of 
Bern (Switzerland).  
 
Table 2. Number of dogs from different dog breeds included in the studies. This table was adapted 
from Olsson et al., Vet. Immunol. Immunopathol. 2014 Aug; 160(3-4): 255-259, with permission from 
Elsevier. 
Breed Abbreviation Study 1 Study 2 Study 3 Total 
American Staffordshire bullterrier - 13 - - 13 
Bearded collie - 49 - - 49 
Belgian shepherd BSD 10 - - 10 
Berner sennen - 21 - - 21 
Border collie - 20 - - 20 
Boxer - 20 - - 20 
Bullterrier - 14 - - 14 
German shepherd GSD 319 207 516 516 
Giant schnauzer - 20 - - 20 
Golden retriever GR 168 - 187 187 
Hovawart HWD 19 - - 19 
Jämthund - 19 - - 19 
Labrador retriever LR 141 - 302 302 
Leonberger - 20 - - 20 
Norwegian elkhund NED 14 - - 14 
Nova Scotia duck tolling retriever NSDTR 11 - - 11 
Rottweiler - 20 - - 20 
Samoyed - 19 - - 18 
Shar Pei SP 157 - 96 157 
Staffordshire bullterrier - 20 - - 20 
Standard Poodle - 137 - - 137 
Tibetan spaniel - 16 - - 16 
Total population  1247 207 1101 1623 
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3.1.2 Wolf samples 
Blood samples were collected from 150 free-ranging Scandinavian wolves in the winters (December–
March) from 1998 through 2014 primarily from the central region of Sweden and Norway (59–61°N, 
11–15°E, [Table 3]). Ten individuals were sampled in northern Sweden, partially at the border to 
Finland. These 150 wolves correspond to approximately 75 % of the entire free-ranging wolf 
population in Sweden and Norway. The individuals were chemically immobilised for radio collaring, 
health assessment, and sampling of biological materials. Blood was collected in tubes with clot 
activating factor (Venoject IIsystem, Terumo Europe N.V., Leuven, Belgium). The tubes were kept at 
room temperature for 1–2 h to ensure complete coagulation. Serum was then separated by 
centrifugation and stored at -20 °C until use. Thirteen samples were collected from wolves living in 
captivity. The samples were collected from chemically immobilised individuals during routine 
check-ups. Blood was collected in tubes with gel and clot activating factor (Venoject
®
 IIsystem, 
Terumo Europe N.V., Leuven, Belgium) and treated as described above. 
Blood samples from 33 free-ranging Canadian wolves were collected in Nunavut and the rest of the 
North-West Territories in Canada in March 2012 or June 2013 (Table 3). The individuals were 
chemically immobilised for radio collaring, health assessment, and sampling of biological materials. 
Blood was collected in red top vacutainer tubes with clot activating factor (Becton, Dickson and 
company, Franklin Lakes, NJ, USA) and treated as described above.  
Capture of free-ranging wolves was approved by the Ethical Committee on Animal Experiments in 
Uppsala, Sweden, by the National Animal Research Authority in Oslo, Norway and the Northwest 
Territories Wildlife Care Committee in Yellowknife, Canada. 
 
Table 3. Number of Canadian and Scandinavian wolves 
    Study 4 Study 5 Total 
Scandinavian 
wolves 
Captive 13 - 13 
Free-ranging 58 92 150 
Total 71 92 163 
Canadian wolves 
 
- 33 - 
 
3.2 DNA EXTRACTION 
Genomic DNA was extracted from EDTA blood samples using Qiagen mini- and/or midiprep 
extraction kits (Qiagen, Hilden, Germany) or from whole blood using the phenol-chloroform or the 
salting out method.  
 
3.3 SERUM IMMUNOGLOBULIN CONCENTRATIONS 
Total serum IgA concentrations were determined by enzyme-linked immunosorbent assay (ELISA) at 
room temperature using non-commercial canine reference samples with known IgA concentrations, as 
described previously [124, 125]. All samples were quantified at least two times. Samples showing 
Canine disease models for IgA deficiency 
 
16 
strong variation between the individual measurements were run again and potential outliers were 
subsequently excluded.  
For studies 1, 3, 4 and 5, polyclonal goat anti-dog IgA antibodies (AbD Serotec, Oxford, UK) and 
alkaline phosphatase-conjugated polyclonal goat anti-dog IgA antibodies (Bethyl Laboratories, 
Montgomery, TX, USA) were diluted 1:2,000 with carbonate-bicarbonate buffer (0.05 M, pH 9.6) or 
Tris-buffered saline and Tween (TBST) respectively. Samples were diluted 1:25,000, 1:50,000 and 
1:100,000 with phosphate-buffered saline with Tween (PBST). Para-Nitrophenylphosphate (PNPP) 
was used as substrate.  
For studies 2 and 4, polyclonal goat anti-dog IgA antibodies (AbD Serotec, Oxford, UK), monoclonal 
mouse anti-dog IgA antibodies (AbD Serotec, Oxford, UK) and alkaline phosphatase-conjugated 
polyclonal goat anti-dog IgA antibodies (Jackson Immunoresearch, West Grove, PA, USA) were 
diluted 1:2,000 in PBST. All samples were diluted three times as described above and PNPP was used 
as a substrate. 
 
3.4 STATISTICS 
All descriptive statistics were calculated using routine procedures and software such as GraphPad 
(La Jolla, CA, USA), IBM SPSS (Armonk, NY, USA) and R (www.r-project.org). Normal 
distribution of IgA concentrations was tested by D’Agostino normality test. The number of animals in 
different groups was assayed for significance by Fisher’s exact test (study 2). The effect of age, sex, 
subpopulations and/or CAD on IgA concentration was assessed either by Spearman correlation 
test (studies 1 and 4), Pearson’s correlation coefficient (study 2) or Kendall’s rank correlation 
test (study 5). Mann-Whitney test (studies 1 and 5) or Welch two-sample t-test (study 2) was used to 
compare the IgA concentrations between different groups of animals. Differences were considered 
significant if p<0.05.  
 
3.5 GENOME-WIDE ASSOCIATION STUDY  
Genome-wide scans were performed for 1,101 dogs (516 GSD, 187 GR, 302 LR and 96 SP) with 
previously determined IgA concentrations using the Illumina 170k Canine HD Bead-Chip (Illumina, 
San Diego, CA, USA). A further 179 GSD were successfully genotyped, of which 91 were CAD cases 
and 88 were healthy controls.   
Quality control was conducted; non-informative markers, markers with a low call rate (≤0.95) and 
markers not in Hardy-Weinberg equilibrium were removed to minimise potential bias and error in 
GWAS results. 
In study 3, an association analysis of CAD was performed in GSD with IgA concentrations (as scale 
measure) and age at sampling as covariates.  
In study 4, an association of IgA concentrations with genetic markers was analysed. Age at sampling 
was used as covariate. A different GWAS was performed in each of the four breeds separately. The 
IgA concentrations were divided into groups of percentile intervals, hence the analysis was run in a 
close-to-continuous manner. A subpopulation assignment was included in the analysis as an additional 
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covariate only for GSD; cases and controls were included for this analysis. All individuals with IgA 
concentrations lower than the 25
th
 percentile were considered cases. Controls were all individuals with 
IgA concentrations higher than the 75
th
 percentile.  
To control for cryptic relatedness and population sub-structure a mixed model approach was applied 
in both studies. Genome-wide significance was defined as p-values below 0.05 after 100,000 
permutations or by using an empirical threshold (97.5 % confidence interval [CI]) calculated from the 
distribution of p-values and after permutations. 
 
3.6 SEQUENCING OF THE IGHA GENE LOCUS 
The IgA heavy chain constant region gene (IGHA), encoding the heavy chain constant region (CH1 to 
CH3) was sequenced in genomic DNA from the blood of two wolves. The gene was amplified by 
polymerase chain reaction (PCR) using primers targeting the IGHA gene in dogs: 
5’ CATGAAGACCTGTGCATTTC TCA 3’, 
5’ AGGGACTCAATTGTGAGGAGGAA 3’. 
The resulting products were cloned into a pMD19-T vector and sequenced by Sanger sequencing.  
 
3.7 IMMUNODIFFUSION 
Serum samples from dog and wolf were analysed for identity by double immunodiffusion, as 
described previously [126], using polyclonal goat anti-dog IgA antibodies (AbD Serotec, Oxford, UK) 
and monoclonal mouse anti-dog IgA antibodies (AbD Serotec, Oxford, UK). Antisera and serum 
samples were added to holes with a defined distance in an agarose matrix. The samples were allowed 
to diffuse in the matrix.  
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4 RESULTS 
4.1 SERUM IGA CONCENTRATIONS AND PREVALENCE FOR IGAD IN DOGS 
4.1.1 IgA concentrations in different dog breeds 
The measured IgA concentrations range from 0.01 g/l to 3.0 g/l (Figure 2). The concentrations vary 
widely among the 22 different purebred dog breeds analysed. The SP stands out as the most high-risk 
breed for low median serum IgA concentrations followed by HWD, NED, NSDTR, BSD, American 
Staffordshire terrier, Bullterrier, GSD, GR, LR and Staffordshire bullterrier. 
The difference in IgA concentrations between males and females as well as castrated and 
non-castrated dogs was found to be insignificant. A positive correlation between IgA concentrations 
and age was found.  
 
 
Figure 2. IgA concentrations measured for 22 different dog breeds. This figure was adapted from 
Olsson et al., Vet. Immunol. Immunopathol. 2014 Aug; 160(3-4): 255-259, with permission from 
Elsevier. 
 
4.1.2 Defining an IgAD cut-off 
In accordance with previously suggested cut-offs for IgAD [95, 98, 99, 102], we calculated a 95 % CI 
of the mean resulting in a cut-off of 0.26 g/l for the total population of 1,623 dogs. Due to the strong 
variation in IgA concentrations among different breeds, a breed-specific cut-off might be preferred.  
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4.1.3 Prevalence of IgAD in different dog breeds 
Low serum IgA concentrations or even overt deficiency have previously been found in 
the SP [98, 100], the GSD [104, 105, 107, 109] and Beagle dogs from selected kennels [95, 101]. 
Our studies suggest an average prevalence of IgAD in the investigated dog breeds of 15 % (Figure 3). 
Furthermore, the following five dog breeds show an increased prevalence for IgAD compared to the 
average: SP, HWD, NED, NSDTR and BSD.  
 
 
Figure 3. Prevalence of IgAD in different dog breeds. 
 
4.2 SERUM IGA CONCENTRATIONS AND PREVALENCE OF IGAD IN 
WOLVES 
4.2.1 Molecular identity of dog and wolf IgA 
The sequenced IGHA gene in wolves has shown complete sequence homology to one of the four 
known gene variants [89] in dogs. Moreover, the fused precipitation lines indicate that the applied 
detection antibodies bind to the same epitope in the IgA molecule in dog and wolf (Figure 4) [124].  
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Figure 4. Double immunodiffusion showing binding of 
one of the detection antibodies to IgA in serum samples 
from dogs and wolves. This figure was adapted from 
Frankowiack et al., Dev. Comp. Immunol. 2013 Jun; 
40(2): 180-184, with permission from Elsevier. 
 
 
4.2.2 IgA concentrations in wolves 
The IgA concentrations in wolves range from 0.01 g/l to 0.23 g/l. No sex- or age-dependency has been 
found. Furthermore, no difference has been found between free-ranging and captive wolves.  
Scandinavian and Canadian wolves differ significantly in their IgA concentrations. The median IgA 
concentration for Scandinavian wolves is 0.05 g/l and 0.18 g/l for Canadian wolves. 
Applying an arbitrary cut-off at 0.1 g/l, the average prevalence for IgAD in Scandinavian wolves is 
80 %. The prevalence of IgAD in wolves from North America is only 14 %. 
 
4.3 GENETIC ASSOCIATION OF IGAD AND CAD 
4.3.1 Genetic association of CAD and IgAD 
Low serum IgA concentrations correlate strongly to the CAD phenotype in GSD. In total, 19 SNPs on 
CFA27 show a significant association to CAD. Furthermore, these 19 SNPs have been found to form 
a 1.5 Mb-long associated haplotype with an 86 % correlation with the case and control haplotype 
pattern. The associated haplotype includes eight genes, with the top two SNPs surrounding the gene 
plakophilin 2 (PKP2).  
 
4.3.2 Genetic association of IgAD 
In the association analysis performed in four dog breeds prone to low IgA concentrations, 35 genomic 
loci were found to be suggestively associated. However, there were no overlapping association signals 
in the different breeds. 
In GSD, three loci on CFA5, CFA8 and CFA23 showed a significant association with IgA 
concentrations. The first locus on CFA5 is around 1 Mb long, consisting of 14 SNPs. Based on the 
SNPs in LD with the top SNP, a region around 1.7 Mb long was identified. This region consists of 
18 SNPs and it resulted in 12 different haplotypes. Two of the haplotypes were defined as risk 
haplotypes, one as an IgA concentration-independent haplotype and nine as rare haplotypes. Only the 
gene kin of IRRE-like protein 3 (KIRREL3) is harboured by these haplotypes, despite its size.  
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Two single SNPs on CFA8 and CFA23 showed significant association. The CFA8 top SNP is in high 
LD with three SNPs spanning a region of about 0.5 Mb. Eleven haplotypes could be defined from this 
region. None of these haplotypes were found to convey either a risk for or a protection from low IgA 
concentrations. However, the region harbours 13 genes, such as goosecoid homeobox (GSC), 
resistin-like beta (RETNLB), protein phosphatase 4 (PPP4R4), and 10 members (member 1, 2, 3-6,  
9-13) in the Serpin peptidase inhibitor family (SERPINA). The CFA23 top SNP is located in the intron 
of the gene G protein-coupled receptor 149 (GPR149) and is not in LD with any other SNP. 
In SP, a significant association to a region on CFA28 was found. The region is part of a ~20 kb-long 
haplotype. In total, two rare haplotypes, two common haplotypes, four risk haplotypes, and one 
protective haplotype were defined. A significant difference in IgA concentrations between the risk and 
the protective haplotype was found in homozygous dogs. Furthermore, both the dogs homozygous for 
the risk haplotype and the dogs heterozygous for the risk haplotype show a significant difference in 
IgA concentration. The haplotype spanned the first intron of the gene slit homolog 1 (SLIT1).  
Pathway analysis unveils significant connectivity between genes in the IgA associated regions across 
three breeds (GSD, GR and SP). The results indicate that around 45 % of the enriched genes are 
involved in inflammation. Gene set enrichment analysis indicates the involvement of, amongst others, 
transcriptional activity, haematopoiesis and regulation of cell growth.  
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5 DISCUSSION 
5.1 IGA CONCENTRATIONS AND IGAD IN DIFFERENT DOG BREEDS 
The proportion of dogs with a low IgA concentration or even an overt IgAD, as well as the range of 
IgA concentrations, has been found to vary widely among different breeds. The inter-breed variability 
makes it difficult to establish a generally accepted, physiologically proven cut-off for IgAD. 
Previously suggested cut-offs in different dog breeds include 0.3 g/l [100], 0.22 g/l [102], 
0.18 g/l [95], and 0.15 g/l [98, 99], these being higher than the cut-offs we chose. In agreement with 
some studies, we suggest the lower limit of the 95 % CI for the mean in the studied population to be 
used as a cut-off [95, 98, 99].  
Most purebred dogs have low levels of genetic variation caused by founder effects, strict breeding 
practices and reproductive isolation. As a consequence, these breeds show a very high susceptibility to 
one or more genetic diseases [40, 127]. IgAD appears to be one of the diseases shared among multiple 
breeds.  
The SP is known to be a high-risk dog breed for IgAD [98, 100] and it stands out as the breed with the 
highest prevalence of IgAD. Amongst the other dog breeds with a considerably increased prevalence 
are the HWD, the NED and the GSD; at least for the latter, inconsistent results have previously been 
published. Normal faecal IgA concentrations [103] and a larger variance in serum IgA concentrations 
as compared to other breeds [102] have been reported, as well as low IgA concentrations or IgAD in 
faeces [109] and serum [105–107]. Our results suggest that the GSD is a high-risk breed for 
IgAD [97]. 
 
5.2 IGAD-ASSOCIATED DISEASES IN DOGS 
In humans, IgAD is associated with autoimmune diseases such as SLE and celiac disease (CD) [16]. 
In dogs, IgAD is known to increase susceptibility to immune-mediated diseases [95].  
The GSD has an exceptionally high susceptibility to immunological diseases or immune-related 
disorders including skin as well as gastrointestinal problems, such as CAD [128, 129]. We found a 
significant difference in IgA concentrations in CAD cases as compared to CAD controls that indicates 
a functional role for IgA in the aetiology of CAD [125]. Furthermore, we identified the gene PKP2 as 
a target gene. The protein encoded by PKP2 is involved in linking cadherins to intermediate filaments 
in the cytoskeleton [130]. Degradation processes in the surface of the skin are known to be common in 
skin diseases including atopic dermatitis [131], underlining that PKP2 is a good candidate gene for 
CAD. Furthermore, altered mRNA expression of PKP2 has been detected between atopic and healthy 
skin and even correlated with clinical severity in atopic skin [132]. 
 
5.3 GENETIC ASSOCIATIONS WITH IGAD IN DOGS 
Our results suggest that canine IgAD is a polygenetic, multifactorial disease. Results from our GWAS 
performed in four breeds prone to low IgA concentrations identified risk haplotypes and target genes 
like KIRREL3, SERPINA9 and SLIT1. These genes are known to play a role in naïve B cell 
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maintenance and the regulation of haematopoiesis in the bone marrow [133–139]. Even though the 
molecular basis of IgAD is unknown, defects were suggested at several steps, including the stem cell 
level [140]. Furthermore, most patients with IgAD were found to have a lower percentage of 
class-switched memory B cells [141], or both memory B cells and class-switched memory B cells, as 
compared to the healthy controls [142]. Interestingly, a reconstitution of IgA production could be 
demonstrated in IgAD subjects by in-vitro induction of class-switch recombination (CSR) through 
CD40 together with IL-4 or IL-10, or IL-21 exclusively [143–148]. This suggests that a lack of one or 
more essential signals following class-switching may result in a selective elimination of IgA
+
 B cells.  
In humans, a mechanistic and genetic difference between low concentrations of serum IgA and IgAD 
has been suggested [149]; contrary to humans, there is no clear distinction between low concentrations 
and IgAD in dogs. In conclusion, the background IgAD in dogs might be equivalent to low serum IgA 
concentrations in humans and thus explain why, at this stage, we were not able to prove homology to 
human IgAD-associated genes for our candidate genes. 
 
5.4 DLA AND AUTOIMMUNE DISEASES  
In both humans and dogs the class II region of the HLA and DLA respectively, is one of the most 
important genetic risk factors for autoimmune disease [74, 150]. As a consequence of a shrinking 
population size, geographic isolation of populations or selective breeding for specific traits, the 
genetic diversity of the DLA can be limited. What follows are strong inter-breed, low intra-breed 
polymorphisms and high levels of homozygosity in 35 % [72] to 40 % [67] of the DLA class II region 
in purebred dogs [67]. 
Consequently, the breed-specific distribution of DLA haplotypes [67, 72, 151] and the decrease in 
genetic diversity might cause the breed-specific increases in disease predisposition of 
immunodeficiencies such as IgAD [97], autoimmune diseases like canine immune arthritis [152], 
diabetes mellitus [153–155], SLE [86], and cancer [67]. Studies on diabetes mellitus have found 
similar risk-associated haplotypes and genotypes in different susceptible breeds [153] confirming this 
notion.  
Similarly to the human HLA, the DLA might not explain the complete heritability of complex 
diseases. It might indicate a link to other genetic markers outside the DLA or to genetic variations in 
the form of polymorphisms or gene copy number variation (CNV) elsewhere in the genome. Such a 
link has been found for SLE in humans [156]. Consequently, alleles inside the DLA might not only 
represent a potential genetic cause for a disease, but might also be an indicator for disease 
susceptibility.  
Although studies in humans have found associations between IgAD and the HLA [20, 27], no 
association has yet been found with the DLA. The lack of a physiologically proven cut-off makes a 
distinction between cases and controls challenging. Strong, but not significant, day-to-day variations 
in IgA concentrations have also been found in saliva, tears and faeces [93, 103]. Since mucosal IgA is 
the main source of serum IgA in dogs [92], one could assume similar variations of serum IgA. 
Unfortunately, due to the complexity involved in sample drawing, a repeated sampling of the dogs, 
albeit highly desirable, might not be possible to achieve.  
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Despite breed-specific differences in the DLA, different dog breeds susceptible to diabetes mellitus 
show similar risk haplotypes and alleles [153]. Assuming an analogous underlying disease cause for 
IgAD, genotyping could help to increase the power of a GWAS due to further population 
stratification.  
Although the applied chip allows for genome-wide genotyping with a uniform coverage, including the 
DLA, some of the SNPs failed due to technical reasons or quality control. Even though the majority of 
SNPs that failed quality control has been excluded due to a low minor allele frequency (MAF), actual 
mutations or variants might have been missed.  
 
5.5 IGAD IN WOLVES 
The nuclear coding-DNA sequence from the domestic dog differs only by 0.04 % from the gray 
wolf [41, 77]. As a result of this close relationship within wolf-like canids, genetic tools developed for 
dogs are usually applicable to wolves as well [77, 157]. SNPs identified in the domestic dog can 
therefore be used to characterise variations in wild wolves [158].  
We could prove complete sequence homology of the IGHA gene in wolves to one of the four known 
gene variants in dogs [89, 124]. Moreover, the antibodies applied for the quantification of serum IgA 
concentrations in dogs and wolves have been found highly reliable, because of the strong correlation 
between the results obtained using the two different sets of antibodies and a unique line of 
precipitation in immunodiffusion [124].  
High levels of inbreeding in the Scandinavian wolf population might be the cause for the difference in 
serum IgA concentrations displayed by Canadian and Scandinavian wolves [159, 160]. Despite the 
observation that reasonably high levels of DLA diversity can be maintained in small 
populations [161], the Scandinavian wolf population is an exception as it was established by only 
three animals [162, 163]. The breeding restriction-dependent reduction in genetic variation could have 
led to an increased proportion of disease-associated DLA alleles or haplotypes in comparison to the 
Canadian wolves. Therefore, a potential enrichment of the same genetic risk factors (supposedly in the 
DLA region) in certain high-risk dog breeds as well as the Scandinavian wolf population might be the 
cause for the increased prevalence of IgAD. These risk factors might have been enriched during the 
domestication and passed on to certain dog breeds. This would explain the breed-specific variation in 
IgA concentrations, the prominent differences in disease prevalence as well as the similarly low IgA 
concentrations in Scandinavian wolves and SP dogs.  
Parts of the DLA class II genes in gray wolves from North America were found to be identical in 
structure to the DLA of domestic dogs with similar polymorphisms at each of the DLA class II 
sites [164]. Thus, the combination of DLA class II alleles might be under strong maintaining pressure. 
Even though wolves from North America had a few dog DLA alleles, Canadian wolves in particular 
showed high levels of variation in the DLA class II region [164]. A reduced susceptibility to IgAD 
might thus be the result of a larger gene pool in the North American wolf population. 
Interestingly, data on the DLA class II alleles in wolves from Scandinavia [162] and North 
America [164] indicated only a minor overlay. However, this data has to be interpreted with caution, 
since it is based on a limited number of animals.  
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5.6 TWINS AS DISEASE MODELS FOR IGAD 
Twins, in particular monozygotic twins discordant for IgAD, provide a unique possibility to study the 
complex interplay of genes and environment in propensity to disease. So far, there are seven 
references on serum IgA concentrations in twins [165–171]. Three of them are case reports [167–169] 
and two studies suggest either a genetic influence on serum IgA concentrations [165] or a combination 
of genetic and environmental influences [166].  
More recent studies suggest non-HLA or even non-genetic predisposing risk factors for the 
development of IgAD [170, 172]. One study on the prevalence of IgAD among patients with type 1 
diabetes (T1D), which is known to be higher compared with the general population [16, 173], suggests 
an incomplete penetrance for certain HLA-determined Ig deficiencies [170]. The other study finds an 
increase in disease prevalence among twins compared to the healthy population which is not explained 
by a genetic association with the HLA. Furthermore, the heritability for IgAD has been found to 
be 35 % [172].  
The problem of missing heritability is shared by most common diseases [174–176] and mapping of 
complex human diseases finds many mutations outside known genes that are likely to alter gene 
regulation rather than the coding sequence [177]. The findings described in here stress the importance 
of non-HLA genetic differences or environmental factors and support the conclusions drawn from the 
studies in dogs and wolves. 
 
6 FUTURE PERSPECTIVES 
6.1 ESTABLISHMENT OF A PHYSIOLOGICALLY PROVEN CUT-OFF FOR 
IGAD 
A physiologically proven cut-off is crucial to distinguish between low concentrations of IgA and 
IgAD. Unfortunately, there is no generally accepted cut-off in dogs as yet. Even if the majority of 
animals displays no clinical symptoms [107], low IgA concentrations resemble human IgAD in a 
proportion of dogs. Hence, an additional screening of medical records might help identify dogs with 
recurrent infections, especially in the skin and the upper respiratory tract [95, 100, 105] as well as an 
increased susceptibility to immune-mediated diseases [95]. Their IgA concentrations could 
consequently be compared to a control group in a breed-specific manner.  
 
6.2 IGAD AND AUTOIMMUNE DISEASES  
An in-depth analysis of medical records would also allow for the investigation of an association 
between IgAD and immune-mediated diseases including autoimmune diseases and allergies. There is 
a well-established connection between human IgAD and autoimmune diseases [16]. Furthermore, we 
found indications for IgA to play an important role in the aetiology of CAD [125]. 
Despite the complexity involved in drawing multiple samples from the same animal, it would allow 
for analysis of the variation in IgA concentrations in dogs. This is of particular interest since seasonal 
fluctuation of IgA concentrations are known in humans [178]. Furthermore, IgAD in humans can 
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appear and disappear without a known cause [2]. Multiple samples could help confirm the permanent 
status of the deficiency in the animals.  
In summary, not only could a retrospective analysis of the medical records help to establish a 
physiologically proven cut-off for IgAD, it could also further substantiate the similarities in disease 
manifestation in humans and dogs. 
 
6.3 DLA HAPLOTYPE ANALYSIS 
Breed specificity in the prevalence of IgAD [97] and the haplotype distribution [67, 72, 151] indicate 
a possible association between IgAD and the DLA. The genotype data from the GWAS could be used 
to impute the DLA haplotypes in the study cohorts and to investigate the presence of risk-conveying 
DLA alleles or haplotypes similar to ones known in humans (see 1.2). Ultimately, GWAS could be 
run on the proportion of cases harboring a respective risk haplotype. This way, the power of the 
analysis would be increased due to the exclusion of genetic variance in the DLA.  
The genotype array used allows for genome-wide genotyping of more than 170,000 SNPs, which 
uniformly cover the whole genome, including the DLA. Should further genotype information be 
needed, despite the strong LD, sequencing of parts of the DLA class II region might be required. In 
this case, sequencing of only one gene of the DLA class II region might be sufficient, due to the small 
number of possible alleles at each locus in purebred dogs [74]. 
Similarly to dogs, wolves from both Canada and Scandinavia could be genotyped; their DLA 
haplotypes could be imputed and compared. It can be assumed that the Scandinavian wolves display a 
much lower diversity of the DLA region, since they represent a much smaller population which is also 
prone to inbreeding (see 5.5).  
It is known that wolves from North America and domestic dogs share similarities in their DLA class II 
genes [164]. One should investigate if this accounts also for potential IgAD risk-haplotypes. 
Furthermore, a comparison of the DLA haplotypes from wolves and dogs with IgAD might support 
the idea that IgAD is a breeding-enriched phenomenon that has been passed on to some purebred dogs 
from the gray wolf. Finally, it should be analysed if there are greater similarities between the DLA 
haplotypes of the Scandinavian wolves and Canadian wolves or one of the high-risk dog breeds. A 
limitation to running GWAS on these wolves is the size of the available sample cohort. Even for a 
simple multiplicative risk model, 100 cases and 100 controls are needed, according to power 
calculations, to detect a fivefold risk allele in 98 % of data sets [40].   
 
6.4 WHOLE-GENOME SEQUENCING  
In common variable immunodeficiency (CVID), another primary immunodeficiency, 
disease-associated CNVs have been found [179]. However, array-based genotyping methods do not 
allow for the detection of structural variants, such as CNV, prediction of functionality, non-coding 
mutations and genes located in non-conserved elements or in complex regions with low sequence 
coverage. To aggravate this situation, structural variants in dogs are poorly understood and until today 
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there are only five large studies on structural variants in dogs using comparative genomic 
hybridisation (CGH) [180]. 
One approach to target structural variants, genetic differences outside the DLA and outside SNPs 
included on the array is whole genome sequencing. DNA sequences from Canadian and Scandinavian 
wolves could thus be compared in an attempt to identify differences that might account for different 
disease prevalence for IgAD.  
 
6.5 WOLF SAMPLES FROM DIFFERENT POPULATIONS 
More serum samples from wolves, ideally from different populations could be used to investigate 
whether low serum IgA concentrations are unique for the Scandinavian wolves. Additionally, an 
assessment on whether low IgA concentrations have a negative effect on the health and fitness of 
these wolves might be informative. For this purpose, it might be feasible to focus on captive wolves as 
regular health checkups are quite common for most of them.  
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7 CONCLUSIONS 
The dog displays an appealing disease model for IgAD. Not only do dogs with low serum IgA 
concentrations resemble human IgAD from a clinical point of view but there is also a genetic 
background present in canine IgAD. Serum IgA concentrations were found to differ between different 
dog breeds. Moreover, several additional dog breeds were identified as high-risk breeds. 
GWAS have identified new, highly interesting target genes associated with low concentrations of 
serum IgA using a novel percentile groups-approach that allowed for the establishment of 
breed-specific cut-offs and the performance of analysis in a close to continuous manner. The results 
suggest that genetic markers involved in B cell development and haematopoiesis play an important 
role in canine IgAD. Furthermore, our results suggest that canine IgAD is a polygenic, multifactorial 
disease.  
IgA concentrations were found to be correlated with the immune-related disease CAD and a novel 
target gene was found to be associated with CAD. Furthermore, our results indicate that Scandinavian 
wolves might represent another high-risk population for IgAD possibly sharing a similar genetic 
background with high-risk dog breeds.  
Our results suggest additional studies, especially on a physiologically relevant cut-off and genotyping 
of the DLA in different dog breeds and wolves from Canada and Scandinavia which will allow for 
investigation of genetic association inside and outside the DLA. 
  
 
  
Marcel Frankowiack 
 
 29 
8 POPULAR SCIENCE SUMMARY 
The dog, our furry companion, believe it or not, has an incredible impact on human health; an impact 
that goes beyond animal-assisted therapy to increase social behaviour or the detection of cancer and 
diabetes by disease-characteristic smells.  
The story of the dog began around 15,000 years ago when it emerged from its ancestor, the gray wolf. 
Since then, humans have selected dogs with desirable traits and thereby strictly reduced the size of the 
available breeding pool. Over time, the dog’s genetic material started to change resulting in strong 
variations between different dog breeds, but very limited variation within individual breeds.  
Today, the dog’s genes are arranged in long blocks that are characteristic to individual dog breeds. 
These blocks help researchers to perform genetic studies in dogs; however they also increase the dog’s 
susceptibility to diseases.  
IgA deficiency (IgAD) is one such disease and individuals suffering from it lack the ability to produce 
IgA antibodies. Since IgA protects the body from invading pathogens by covering the mucosal 
surfaces of the gastrointestinal and respiratory tracts, individuals with IgAD are likely to experience 
recurrent infections at these sites. Interestingly, the clinical manifestations of IgAD are similar in 
humans and dogs.  
The results presented herein suggest that the dog is a suitable model to study the background of human 
IgAD. More specifically, we found IgA concentrations and the number of dogs with IgAD to be 
breed-specific, suggesting the involvement of genes in the development of the disease.  
By selecting dog breeds with a high susceptibility to IgAD and analysing their genes, we identified 
genetic markers involved in formation of blood cells to play an important role in the development of 
the disease.  
We also found very low IgA concentrations in Scandinavian, but not in Canadian, wolves so further 
genetic studies are currently planned to help identify common genetic denominators in dog breeds 
with a high prevalence of IgAD and wolves from Scandinavia. These studies will also investigate the 
genetic differences in Canadian and Scandinavian wolves, which could account for the observed 
difference in IgA concentrations.  
In conclusion, this study portrays dogs and wolves as appealing disease models to study the 
background of IgAD. 
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